Tech Company Financing Transactions

Dicerna Pharmaceuticals Funding Round

Dicerna Pharmaceuticals secured a $25 million Series B investment round on 8/11/2010. Investors included Domain Associates, Abingworth and Oxford Bioscience Partners.

Transaction Overview

Company Name
Dicerna Pharmaceuticals
Announced On
8/11/2010
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series B
Investors

Domain Associates (Lead Investor) (Brian Halak)

Abingworth (Vincent Miles)

Oxford Bioscience Partners

Skyline Ventures (Stephen Hoffman)

Proceeds Purpose
Proceeds from the financing will be used to advance Dicerna's lead in-house program in oncology towards clinical development and progress its other preclinical programs. The company also plans to use the proceeds to continue to develop conjugated drug delivery systems, which combine Dicerna's DsiRNA molecules with targeting moieties such as peptides, aptamers or antibodies, potentially allowing for direct delivery into specific cells of interest.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
33 Hayden Ave.
Lexington, MA 02421
USA
Phone
(617) 621-8097
Website
www.dicerna.com
Email Address
[email protected]
Overview
Dicerna (NASDAQ: DRNA) is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes.
Profile
Dicerna Pharmaceuticals LinkedIn Company Profile
Social Media
Dicerna Pharmaceuticals Company Twitter Account
Company News
Dicerna Pharmaceuticals News
Facebook
Dicerna Pharmaceuticals on Facebook
YouTube
Dicerna Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Douglas Fambrough
  Douglas Fambrough LinkedIn Profile  Douglas Fambrough Twitter Account  Douglas Fambrough News  Douglas Fambrough on Facebook
Chief Financial Officer
Jack Green
  Jack Green LinkedIn Profile  Jack Green Twitter Account  Jack Green News  Jack Green on Facebook
Chief Medical Officer
Ralf Rosskamp
  Ralf Rosskamp LinkedIn Profile  Ralf Rosskamp Twitter Account  Ralf Rosskamp News  Ralf Rosskamp on Facebook
Chief Scientific Officer
Bob Brown
  Bob Brown LinkedIn Profile  Bob Brown Twitter Account  Bob Brown News  Bob Brown on Facebook
Vice President
Jennifer Lockridge
  Jennifer Lockridge LinkedIn Profile  Jennifer Lockridge Twitter Account  Jennifer Lockridge News  Jennifer Lockridge on Facebook
VP - Bus. Development
James Weissman
  James Weissman LinkedIn Profile  James Weissman Twitter Account  James Weissman News  James Weissman on Facebook
VP - Operations
David Miller
  David Miller LinkedIn Profile  David Miller Twitter Account  David Miller News  David Miller on Facebook

 

 

Browse more venture capital transactions:

Prev: 8/10/2010: Axis Semiconductor venture capital transaction
Next: 8/11/2010: TetraLogic Pharmaceuticals venture capital transaction

 

Share this article

 

Where The Data Comes From

We report on every notable VC transaction. VC investment data records on this site are derived from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.